sar445877
Recombinant proteinexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 29, 2022 (NCT05584670)
Timeline
Indications
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07133425 | Phase 2 | Feb 5, 2026 | Sanofi, University of Texas at Houston |
| NCT05584670 | Phase 1/Phase 2 (Phase 2) | Nov 29, 2022 | Sanofi |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 2 | 1 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2026 |
2 organizations
Page 1 / 1